Answers are grounded in this paper and cite their sources.
Multiperspective narrative reveals complex management challenges in adrenocortical carcinoma, highlighting the critical need for expert multidisciplinary care and patient advocacy.
Adrenocortical carcinoma (ACC) is a rare and aggressive form of cancer. This article presents a multiperspective narrative describing the experience of a patient treated for ACC, the clinical insights of an endocrinologist, and the advocacy perspective of “Let’s Cure ACC”, a patient association. The patient describes his journey from diagnosis to treatment, disease recurrence, and, ultimately, a disease-free state. Diagnosed at age 45 with locally invasive ACC in 2017, he underwent surgery, chemotherapy, and long-term mitotane therapy. He experienced multiple disease recurrences, repeated surgeries, and chemotherapy, and achieved remission in 2020. Today, the patient remains disease free, although continuing to experience treatment-related adverse effects. He shares the challenges of living with ACC and the effects of treatment on his daily life, particularly adrenal insufficiency (a condition in which the adrenal glands do not produce enough cortisol) complicated by recurrent Addison (adrenal) crises (acute adrenal insufficiency caused by a sudden lack of cortisol, requiring urgent treatment to prevent shock or death). These challenges underscore the importance of patient education, family involvement, and meticulous management of hormone replacement therapy. He emphasizes the importance of being managed through an expert treatment center. The endocrinologist provides an evidence-based perspective on treatment decisions, the role of mitotane in long-term disease control, and the need for ongoing replacement therapy with hydrocortisone to manage adrenal insufficiency following extended mitotane treatment. Finally, the patient association representative emphasizes the unmet informational needs of patients with rare cancers and the pivotal role of advocacy organizations in improving patient and physician awareness of ACC, fostering collaboration, and advocating for better education and support for ACC patients and their families and caregivers. Together, these viewpoints emphasize the need to optimize treatment decisions, strengthen patient–physician collaboration, and share long-term insights to guide care in ACC patients with the aim of achieving the best possible outcomes. Adrenocortical carcinoma is a rare form of cancer that develops in the outer layer of the adrenal glands. Normally, adrenal glands are responsible for producing hormones that manage how the body reacts to stress, uses food, and controls blood pressure. In adrenocortical carcinoma, the tumor can cause an excess release of these hormones, which disrupts how the body functions. Large or fast-growing tumors sometimes invade nearby tissues or press against organs. This article, which has been co-authored by a Swiss patient living in Germany with adrenocortical carcinoma, a specialist physician from Germany (endocrinologist), and a representative from a global patient association for adrenocortical carcinoma, describes the cancer from the perspectives of each author. The patient shares his personal experience, including the challenges of his diagnosis with adrenocortical carcinoma, multiple disease recurrences, long-term treatment, and ultimate achievement of disease remission. The endocrinologist provides more detail on the characteristics of adrenocortical carcinoma and its limited treatment options, as well as the side effects of long-term treatment with mitotane, which is a targeted drug that specifically acts on cancer cells in the adrenal gland. The patient association representative describes the key role of the association in helping patients with adrenocortical carcinoma, providing information and support to patients around the world, while connecting them with the expert care they need. These perspectives highlight the importance of support, education, and strong patient–physician communication when treating individuals with adrenocortical carcinoma.
No takes yet. Share an insight, caveat, or question.
Büdenbender et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: